Unprotected sexual intercourse and injection drug use continue to occur in correctional facilities where HIV infection is prevalent. Some inmates will develop acute symptomatic retroviral syndromes during their incarceration. Since combination antiretroviral treatment of these primary infections may alter the course of HIV disease, we recommend that correctional facilities educate their primary care providers regarding the recognition and treatment of the acute retroviral syndrome.
Get full access to this article
View all access options for this article.
References
1.
BalslevE., Thomsen, H. K., & WeismannK. (1990). Histopathology of acute human immunodeficiency virus exanthema. Journal of Clinical Pathology, 43, 201-202.
2.
BartlettJ. (1997). Medical management of HIV infection. Port City Press. Baltimore, Maryland.
3.
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., HirschM., JacobsenD., KatzensteinD., MontanerJ., RichmanD., SaagM., SchooleyR., ThompsonM., VellaS., YeniP., & VolberdingP. (1997). Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association, 277, 1962-1969.
4.
Craib, K. J. P., Strathdee, S. A., Hogg, R. S., LeungB., MontanerJ., O’ShaughnessyM., & SchechterM. (1997). Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long term mortality in HIV infection. Journal of Infectious Diseases, 176, 798-800.
5.
DorrucciM., RezzaG., VlahovD., PezzottiP., SiniccoA., NicolosiA., LazzarinA., GalaiN., GafaS., & PristeraR. (1995). Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users-Italian seroconversion study. AIDS, 9(6), 597-604.
6.
Dull, J. S., SenP., RaffantiS., & MiddletonJ. (1991). Oral candidiasis as a marker of acute retroviral illness. Southern Medical Journal, 84(6), 733-735.
7.
FaganT.J., WennerstromD., & MillerJ. (1996). Sexual assault of male inmates: Prevention, identification, and intervention. Journal of Correctional Health Care, 3(1), 49-65.
8.
Gaughwin, M. D., Douglas, R. M., LiewC., DaviesL., MylvaganamA., TreffieH., EdwardsJ., & AliR. (1991). HIV prevalence and risk behaviors for HIV transmission in South Australian prisons. AIDS, 5(7), 845-851.
9.
Ho, D. D. (1995). Time to hit HIV, early and hard [Editorial]. New England Journal of Medicine, 334, 450-451.
10.
Kinloch de LoesS., de SaussureP., SauratJ., StadlerH., HirschelB., & PerrinL. (1993). Symptomatic primary infection due to human immunodeficiency virus type 1 Review of 3 1 cases. Clinical Infectious Diseases, 17, 59-65.
11.
LafeuilladeA., PoggiC., TamaletC., ProfiziN., TourresC., & CostesO. (1997). Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. Journal of Infectious Diseases, 175, 1051-1055.
12.
LawsonW., MacherA., DennisonR., FullerP., KaleW., & CoonrodJ. (1991). The clinical management of incarcerated women with HIV disease at the Federal Correctional Institution and the University of Kentucky Medical Center in Lexington, Kentucky-A collaborative model for early intervention and continuity of care [Abstract MD4248]. Proceedings of the Seventh International Conference on AIDS. (p.452-452). Florence, Italy.
13.
LeBoit, P. E. (1992). Dermatopathologic findings in patients infected with HIV. Dermatology Clinics, 10, 59-71.
14.
Macher, A. M., & Goosby, E. P. (1997). Issues regarding antiretroviral treatment for patients with HIV-1 infection [Letter]. Journal of the American Medical Association, 278(15), 1234-1235.
15.
MacherA., GoosbyE., BarkerL., VolberdingP., GoldschmidtR., Balano. K., WilliamsA., HoenigL., GouldB., & DanielsE. (1994). Educating primary care providers about HIV disease: Multidisciplinary interactive mechanisms. Public Health Reports, 109(3), 305-310.
16.
Mellors, J. W., Kingsley, L. A., Rinaldo, C. R., ToddJ., HooB., KokkaaR., & GuptaP. (1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine, 122, 573-579.
17.
Mellors, J. W., Rinaldo, C. R., GuptaP., WhiteR., ToddJ., & KingsleyL. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170.
18.
Mutter, R. C., Grimes, R. M., & LabartheD. (1994). Evidence of intraprison spread of HIV infection. Archives of Internal Medicine, 154(7), 793-795.
19.
NiuM., SteinD., & SchnittmanS. (1993). Primary human immunodeficiency virus type 1 infection: Review of pathogenesis and early treatment interventions in humans and animal retrovirus infections. Journal of Infectious Diseases, 168, 1490-1501.
20.
O’Brien T. R., Blattner, W. A., WatersD., EysterE., HilgartnerM., CohenA., LubanN., HatzakisA., AledortL., RosenbergP., MileyW., KronerB., & GoedertJ. (1996). Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. Journal of the American Medical Association, 276, 105-110.
21.
O’Brien, W. A., Hartigan, P. M., MartinD., EsinhartJ., HillA., BenoitS., RubinM., SimberkoffM., & HamiltonJ. (1996). Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine, 334, 426-431.
22.
Panel on Clinical Practices for HIV Treatment. (1997). U.S. Public Health Service guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Federal Register, 62(118), 33417-33418.
23.
PedersenC., LindhardtB., JensenB., LauritzenE., GerstoftJ., DickmeissE., GaubJ., ScheibelE., & KarlsmarkT. (1989). Clinical course of primary HIV infection: Consequences for subsequent course of infection. British Medical Journal, 299, 154-157.
24.
Perrin, T. H., MarkowitzM., CalandraG., ChungM., & the MRL Acute HIV Infection Study Group. (1997). An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [Abstract #238]. Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections (p. 16-16). Washington, DC.
25.
PolonskyS., KerrS., HarrisB., GaiterJ., FichtnerR., & KennedyM. (1994). HIV prevention in prison and jails: Obstacles and opportunities. Public Health Reports, 109, 615-625.
26.
PontJ., StrutzH., KahlW., & SalznerG. (1994). HIV epidemiology and risk behavior promoting HIV transmission in Austrian prisons. European Journal of Epidemiology, 10, 285-289.
27.
QuinnT. (1997). Acute primary HIV infection. Journal of the American Medical Association, 278, 58-62.
28.
RosenbergE., & CottonD. (1997). Primary HIV infection and the acute retroviral syndrome. AIDS Clinical Care, 9(3), pages 19-19 and 23-25.
29.
SakselaK., Stevens, C. E., RubinsteinP., TaylorP., & BaltimoreD. (1995). HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Annals of Internal Medicine, 123, 641-648.
30.
SchackerT., CollierA., HughesJ., SheaT., & CoreyL. (1996). Clinical and epidemiologic features of primary HIV infection. Annals of Internal Medicine, 125, 257-264.
31.
Solursh, L. P., Solursh, D. S., & Meyer C. A. (1993). Is there sex after the prison door slams shut?. Medicine and Law, 12(3-5), 439-443.
32.
TaylorA., GoldbergD., EmslieJ., WrenchJ., GruerL., CameronS., BlackJ., DavisB., McGregorJ., & FollettE. (1995). Outbreak of HIV infection in a Scottish prison. British Medical Journal, 310, 289-292.
33.
TindallB., HingM., EdwardsP., BarnesT., MackieA., & CooperD. (1989). Severe clinical manifestations of primary HIV infection. AIDS, 3, 747-749.
